Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.
Identifieur interne : 009196 ( Ncbi/Merge ); précédent : 009195; suivant : 009197Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.
Auteurs : Tessa G. Steenbruggen [Pays-Bas] ; Mette S. Van Ramshorst [Pays-Bas] ; Marleen Kok [Pays-Bas] ; Sabine C. Linn [Pays-Bas] ; Carolien H. Smorenburg [Pays-Bas] ; Gabe S. Sonke [Pays-Bas]Source :
- Drugs [ 1179-1950 ] ; 2017.
Abstract
In the last decade, the systemic treatment approach for patients with early breast cancer has partly shifted from adjuvant treatment to neoadjuvant treatment. Systemic treatment administration started as a 'one size fits all' approach but is currently customized according to each breast cancer subtype. Systemic treatment in a neoadjuvant setting is at least as effective as in an adjuvant setting and has several additional advantages. First, it enables response monitoring and provides prognostic information; second, it downstages the tumor, allowing for less extensive surgery, improved cosmetic outcomes, and reduced postoperative complications such as lymphedema; and third, it enables early development of new treatment strategies by using pathological complete remission as a surrogate outcome of event-free and overall survival. In this review we give an overview of the current standard of neoadjuvant systemic treatment strategies for the three main subtypes of breast cancer: hormone receptor-positive, triple-negative, and human epidermal growth factor receptor 2-positive. Additionally, we summarize drugs that are under investigation for use in the neoadjuvant setting.
DOI: 10.1007/s40265-017-0774-5
PubMed: 28616845
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000145
- to stream PubMed, to step Curation: 000145
- to stream PubMed, to step Checkpoint: 000145
Links to Exploration step
pubmed:28616845Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.</title><author><name sortKey="Steenbruggen, Tessa G" sort="Steenbruggen, Tessa G" uniqKey="Steenbruggen T" first="Tessa G" last="Steenbruggen">Tessa G. Steenbruggen</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Van Ramshorst, Mette S" sort="Van Ramshorst, Mette S" uniqKey="Van Ramshorst M" first="Mette S" last="Van Ramshorst">Mette S. Van Ramshorst</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Kok, Marleen" sort="Kok, Marleen" uniqKey="Kok M" first="Marleen" last="Kok">Marleen Kok</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Linn, Sabine C" sort="Linn, Sabine C" uniqKey="Linn S" first="Sabine C" last="Linn">Sabine C. Linn</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Smorenburg, Carolien H" sort="Smorenburg, Carolien H" uniqKey="Smorenburg C" first="Carolien H" last="Smorenburg">Carolien H. Smorenburg</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Sonke, Gabe S" sort="Sonke, Gabe S" uniqKey="Sonke G" first="Gabe S" last="Sonke">Gabe S. Sonke</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands. g.sonke@nki.nl.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28616845</idno><idno type="pmid">28616845</idno><idno type="doi">10.1007/s40265-017-0774-5</idno><idno type="wicri:Area/PubMed/Corpus">000145</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000145</idno><idno type="wicri:Area/PubMed/Curation">000145</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000145</idno><idno type="wicri:Area/PubMed/Checkpoint">000145</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000145</idno><idno type="wicri:Area/Ncbi/Merge">009196</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.</title><author><name sortKey="Steenbruggen, Tessa G" sort="Steenbruggen, Tessa G" uniqKey="Steenbruggen T" first="Tessa G" last="Steenbruggen">Tessa G. Steenbruggen</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Van Ramshorst, Mette S" sort="Van Ramshorst, Mette S" uniqKey="Van Ramshorst M" first="Mette S" last="Van Ramshorst">Mette S. Van Ramshorst</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Kok, Marleen" sort="Kok, Marleen" uniqKey="Kok M" first="Marleen" last="Kok">Marleen Kok</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Linn, Sabine C" sort="Linn, Sabine C" uniqKey="Linn S" first="Sabine C" last="Linn">Sabine C. Linn</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Smorenburg, Carolien H" sort="Smorenburg, Carolien H" uniqKey="Smorenburg C" first="Carolien H" last="Smorenburg">Carolien H. Smorenburg</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Sonke, Gabe S" sort="Sonke, Gabe S" uniqKey="Sonke G" first="Gabe S" last="Sonke">Gabe S. Sonke</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands. g.sonke@nki.nl.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author></analytic><series><title level="j">Drugs</title><idno type="eISSN">1179-1950</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the last decade, the systemic treatment approach for patients with early breast cancer has partly shifted from adjuvant treatment to neoadjuvant treatment. Systemic treatment administration started as a 'one size fits all' approach but is currently customized according to each breast cancer subtype. Systemic treatment in a neoadjuvant setting is at least as effective as in an adjuvant setting and has several additional advantages. First, it enables response monitoring and provides prognostic information; second, it downstages the tumor, allowing for less extensive surgery, improved cosmetic outcomes, and reduced postoperative complications such as lymphedema; and third, it enables early development of new treatment strategies by using pathological complete remission as a surrogate outcome of event-free and overall survival. In this review we give an overview of the current standard of neoadjuvant systemic treatment strategies for the three main subtypes of breast cancer: hormone receptor-positive, triple-negative, and human epidermal growth factor receptor 2-positive. Additionally, we summarize drugs that are under investigation for use in the neoadjuvant setting.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">28616845</PMID><DateCreated><Year>2017</Year><Month>06</Month><Day>15</Day></DateCreated><DateRevised><Year>2017</Year><Month>08</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1950</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>12</Issue><PubDate><Year>2017</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Drugs</Title><ISOAbbreviation>Drugs</ISOAbbreviation></Journal><ArticleTitle>Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.</ArticleTitle><Pagination><MedlinePgn>1313-1336</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40265-017-0774-5</ELocationID><Abstract><AbstractText>In the last decade, the systemic treatment approach for patients with early breast cancer has partly shifted from adjuvant treatment to neoadjuvant treatment. Systemic treatment administration started as a 'one size fits all' approach but is currently customized according to each breast cancer subtype. Systemic treatment in a neoadjuvant setting is at least as effective as in an adjuvant setting and has several additional advantages. First, it enables response monitoring and provides prognostic information; second, it downstages the tumor, allowing for less extensive surgery, improved cosmetic outcomes, and reduced postoperative complications such as lymphedema; and third, it enables early development of new treatment strategies by using pathological complete remission as a surrogate outcome of event-free and overall survival. In this review we give an overview of the current standard of neoadjuvant systemic treatment strategies for the three main subtypes of breast cancer: hormone receptor-positive, triple-negative, and human epidermal growth factor receptor 2-positive. Additionally, we summarize drugs that are under investigation for use in the neoadjuvant setting.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Steenbruggen</LastName><ForeName>Tessa G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Ramshorst</LastName><ForeName>Mette S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kok</LastName><ForeName>Marleen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linn</LastName><ForeName>Sabine C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smorenburg</LastName><ForeName>Carolien H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sonke</LastName><ForeName>Gabe S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands. g.sonke@nki.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drugs</MedlineTA><NlmUniqueID>7600076</NlmUniqueID><ISSNLinking>0012-6667</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2016 Sep 15;22(18):4594-603</RefSource><PMID Version="1">27140927</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2013 Dec 10;109(12):2965-72</RefSource><PMID Version="1">24149178</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2017 Mar 1;28(3):497-504</RefSource><PMID Version="1">27831502</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncotarget. 2014 Aug 30;5(16):6633-46</RefSource><PMID Version="1">24952873</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2015 Dec 03;10(12):e0143643</RefSource><PMID Version="1">26633806</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2011 Aug 20;29(24):3214-23</RefSource><PMID Version="1">21768471</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2005 Feb 2;97(3):188-94</RefSource><PMID Version="1">15687361</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2015 Jul 28;113(3):396-402</RefSource><PMID Version="1">26180927</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Drug Discov. 2015 Feb;14(2):130-46</RefSource><PMID Version="1">25633797</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2015 Jul;16(7):848-58</RefSource><PMID Version="1">26092816</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2015 Aug;26(8):1533-46</RefSource><PMID Version="1">25939896</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2011 Dec 1;29(34):4491-7</RefSource><PMID Version="1">22042958</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2013 Jul;14(8):741-8</RefSource><PMID Version="1">23764181</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Surg. 2017 Feb;213(2):426-432</RefSource><PMID Version="1">27769548</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Cell. 2011 Dec 13;20(6):797-809</RefSource><PMID Version="1">22172724</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2014 Aug;15(9):997-1006</RefSource><PMID Version="1">25035292</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Feb 9;366(6):520-9</RefSource><PMID Version="1">22149876</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Nov 8;367(19):1783-91</RefSource><PMID Version="1">23020162</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2012 Feb;13(2):135-44</RefSource><PMID Version="1">22257523</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA Oncol. 2017 Apr 1;3(4):524-548</RefSource><PMID Version="1">27918777</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2011 Aug;129(1):185-90</RefSource><PMID Version="1">21394499</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2014 Dec;25(12 ):2357-62</RefSource><PMID Version="1">25231953</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2012 Sep;135(2):505-17</RefSource><PMID Version="1">22875744</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2014 Jul 10;371(2):107-18</RefSource><PMID Version="1">24881463</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Metastasis Rev. 2016 Dec;35(4):515-524</RefSource><PMID Version="1">27896521</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2012 Feb 4;379(9814):432-44</RefSource><PMID Version="1">22152853</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Cancer. 2004 Oct;4(10 ):814-9</RefSource><PMID Version="1">15510162</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2005 Oct 20;353(16):1659-72</RefSource><PMID Version="1">16236737</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 Oct 13;365(15):1396-405</RefSource><PMID Version="1">21995387</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2014 Jun;15(7):747-56</RefSource><PMID Version="1">24794243</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2010 Jan 30;375(9712):377-84</RefSource><PMID Version="1">20113825</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2017 Apr 1;35(10 ):1049-1060</RefSource><PMID Version="1">28135148</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7142-7</RefSource><PMID Version="1">21482773</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2017 Jan;161(2):185-190</RefSource><PMID Version="1">27785653</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Breast Cancer. 2015 Apr;15(2):101-9</RefSource><PMID Version="1">25537159</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2015 Sep;16(9):1037-48</RefSource><PMID Version="1">26272770</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2014 Dec;15(13):1493-502</RefSource><PMID Version="1">25456368</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2013 May 28;108(10):2172-7</RefSource><PMID Version="1">23558900</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2015 Apr 1;33(10):1136-42</RefSource><PMID Version="1">25713436</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 Oct 6;365(14):1273-83</RefSource><PMID Version="1">21991949</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BioDrugs. 2017 Feb;31(1):1-36</RefSource><PMID Version="1">28078656</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2011 Feb 20;29(6):660-6</RefSource><PMID Version="1">21220595</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res. 2014 May 15;16(3):R47</RefSource><PMID Version="1">24887359</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Expert Opin Pharmacother. 2016 Nov;17 (16):2179-2189</RefSource><PMID Version="1">27646965</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocr Relat Cancer. 2011 Apr 28;18(3):333-45</RefSource><PMID Version="1">21367843</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Surg. 2015 Feb;261(2):378-82</RefSource><PMID Version="1">24743607</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Jun 28;366(26):2438-41</RefSource><PMID Version="1">22646508</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2014 Mar 4;110(5):1139-47</RefSource><PMID Version="1">24457911</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2017 Jan 3;317(1):37-47</RefSource><PMID Version="1">27918780</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Medicine (Baltimore). 2016 Nov;95(44):e5195</RefSource><PMID Version="1">27858859</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2016 Jun 1;22(11):2650-8</RefSource><PMID Version="1">26783290</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2001 Nov;12(11):1527-32</RefSource><PMID Version="1">11822750</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2012 Jan;13(1):25-32</RefSource><PMID Version="1">22153890</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2014 Apr;144(3):569-76</RefSource><PMID Version="1">24562823</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 Jan 1;30(1):11-8</RefSource><PMID Version="1">22105826</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2015 Jul 1;21(13):2924-31</RefSource><PMID Version="1">25825476</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2011 Aug 27;378(9793):771-84</RefSource><PMID Version="1">21802721</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Res Notes. 2013 Dec 05;6:507</RefSource><PMID Version="1">24304724</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2015 May 9;385(9980):1863-72</RefSource><PMID Version="1">25740286</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2000 Aug 17;406(6797):747-52</RefSource><PMID Version="1">10963602</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2015 Jul;16(7):816-29</RefSource><PMID Version="1">26092818</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res. 2010;12(4):R52</RefSource><PMID Version="1">20646288</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Oncol. 2015 Feb;22(1):33-48</RefSource><PMID Version="1">25684987</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2016 Nov 3;375(18):1738-1748</RefSource><PMID Version="1">27717303</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Ther. 2013 Oct;30(10 ):870-84</RefSource><PMID Version="1">24158787</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 1987 Jan 9;235(4785):177-82</RefSource><PMID Version="1">3798106</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Breast Cancer. 2004 Apr;5(1):63-9</RefSource><PMID Version="1">15140287</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Expert Opin Investig Drugs. 2014 May;23(5):611-28</RefSource><PMID Version="1">24669860</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Sci Transl Med. 2015 Nov 25;7(315):315ra188</RefSource><PMID Version="1">26606967</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2016 Jul 7;375(1):11-22</RefSource><PMID Version="1">27406346</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2017 Apr 11;:JCO2016714147</RefSource><PMID Version="1">28398846</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2005 Oct 20;353(16):1673-84</RefSource><PMID Version="1">16236738</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2017 Mar 25;389(10075):1195-1205</RefSource><PMID Version="1">28215665</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2009 May 1;69(9):3955-62</RefSource><PMID Version="1">19366795</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Epidemiol. 2016 Dec;45:82-90</RefSource><PMID Version="1">27770672</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2012 Nov 15;118(22):5463-72</RefSource><PMID Version="1">22544643</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2014 May;15(6):580-91</RefSource><PMID Version="1">24742739</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2014 Feb;15(2):e58-68</RefSource><PMID Version="1">24480556</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Jun 1;27(16):2630-7</RefSource><PMID Version="1">19380449</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2013 Oct;14(11):1121-8</RefSource><PMID Version="1">24007746</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2016 Feb 20;34(6):542-9</RefSource><PMID Version="1">26527775</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Cancer. 2009 Jul;9(7):463-75</RefSource><PMID Version="1">19536107</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005002</RefSource><PMID Version="1">17443564</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2010 Dec 15;102(24):1845-54</RefSource><PMID Version="1">21098761</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2013 Dec;24(12 ):2978-84</RefSource><PMID Version="1">24136883</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2017 Apr;18(4):545-554</RefSource><PMID Version="1">28238593</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2017 Jan;71:34-42</RefSource><PMID Version="1">27951450</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2013 Jan;14(1):88-96</RefSource><PMID Version="1">23234763</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2016 Jun;17 (6):791-800</RefSource><PMID Version="1">27179402</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Clin Pathol. 2012 Oct;138(4):511-6</RefSource><PMID Version="1">23010705</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2011 Jul;22(7):1561-70</RefSource><PMID Version="1">21135055</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23</RefSource><PMID Version="1">12829800</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2011 Aug;22(8):1736-47</RefSource><PMID Version="1">21709140</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA Oncol. 2016 Jun 1;2(6):751-60</RefSource><PMID Version="1">26914222</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res. 2002;4(5):197-201</RefSource><PMID Version="1">12223124</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>ESMO Open. 2016 Jul 21;1(4):e000073</RefSource><PMID Version="1">27843627</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2005 Dec 7;97(23):1724-33</RefSource><PMID Version="1">16333028</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2016 May 10;34(14 ):1689-701</RefSource><PMID Version="1">26884586</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pathol. 2005 Oct;207(2):139-46</RefSource><PMID Version="1">16088978</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2012 Jun 10;486(7403):353-60</RefSource><PMID Version="1">22722193</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2009 Jul 9;361(2):123-34</RefSource><PMID Version="1">19553641</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Med Genet. 2011 Aug;48(8):520-2</RefSource><PMID Version="1">21653198</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2015 Jan 1;33(1):58-64</RefSource><PMID Version="1">25422488</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 1997 Oct 15;57(20):4593-9</RefSource><PMID Version="1">9377574</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2014 Jul 12;384(9938):164-72</RefSource><PMID Version="1">24529560</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2017 Jan 1;23 (1):26-34</RefSource><PMID Version="1">27126994</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Probl Cancer. 2016 Mar - Aug;40(2-4):141-150</RefSource><PMID Version="1">27816190</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2011 Aug 1;17(15):5132-9</RefSource><PMID Version="1">21558407</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2005 Jun 1;23(16):3676-85</RefSource><PMID Version="1">15738535</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2016 Aug 25;375(8):717-29</RefSource><PMID Version="1">27557300</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2010 Jul 24;376(9737):235-44</RefSource><PMID Version="1">20609467</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2015 Jul;26(7):1488-93</RefSource><PMID Version="1">25897014</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2005 Aug 1;23(22):5108-16</RefSource><PMID Version="1">15998903</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA Oncol. 2016 Nov 1;2(11):1477-1486</RefSource><PMID Version="1">27367583</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2013 Sep;24(9):2278-84</RefSource><PMID Version="1">23704196</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Mar 10;26(8):1275-81</RefSource><PMID Version="1">18250347</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2009 Feb 12;360(7):679-91</RefSource><PMID Version="1">19213681</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2016 Dec 1;22(23 ):5651-5660</RefSource><PMID Version="1">27678458</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2015 Oct 3;386(10001):1353-1361</RefSource><PMID Version="1">26211824</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2005 Jun 1;23(16):3868-9; author reply 3869-70</RefSource><PMID Version="1">15923595</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Expert Opin Biol Ther. 2017 Apr;17 (4):497-506</RefSource><PMID Version="1">28133971</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2016 Aug 15;139(4):882-9</RefSource><PMID Version="1">26946057</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2014 Jul;146(1):15-24</RefSource><PMID Version="1">24842267</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2013 Oct 1;19(19):5505-12</RefSource><PMID Version="1">23965901</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2016 Oct 14;11(10 ):e0164663</RefSource><PMID Version="1">27741288</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Mar 10;27(8):1177-83</RefSource><PMID Version="1">19204201</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2006 May 15;12(10):3085-91</RefSource><PMID Version="1">16707606</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2014 Sep;50(13):2190-200</RefSource><PMID Version="1">24970786</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2015 Feb 15;21(4):763-70</RefSource><PMID Version="1">25480832</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncologist. 2001;6 Suppl 3:30-5</RefSource><PMID Version="1">11346683</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2014 Nov 20;32(33):3744-52</RefSource><PMID Version="1">25332249</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Cancer Ther. 2014 Nov;13(11):2618-29</RefSource><PMID Version="1">25189543</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2007 Jun;18(6):977-84</RefSource><PMID Version="1">17229773</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006243</RefSource><PMID Version="1">22513938</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncogene. 2005 Nov 14;24(50):7455-64</RefSource><PMID Version="1">16288292</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2012 Apr 04;486(7403):395-9</RefSource><PMID Version="1">22495314</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2017 Mar 7;:null</RefSource><PMID Version="1">28270497</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2013 Sep 21;382(9897):1021-8</RefSource><PMID Version="1">23871490</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2011 Nov;130(2):645-55</RefSource><PMID Version="1">21717105</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2015 Jul 20;33(21):2353-60</RefSource><PMID Version="1">26077235</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 Jan 8;372(2):134-41</RefSource><PMID Version="1">25564897</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2014 May;15(6):640-7</RefSource><PMID Version="1">24657003</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2015 Dec 30;10(12):e0145442</RefSource><PMID Version="1">26717149</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Clin Oncol. 2015 Jan;12(1):27-41</RefSource><PMID Version="1">25286972</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 1985 Dec;3(12):1672-7</RefSource><PMID Version="1">4067614</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2007 Aug 15;110(4):876-84</RefSource><PMID Version="1">17620276</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2013 May 10;31(14):1726-31</RefSource><PMID Version="1">23569315</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2016 Nov 17;375(20):1925-1936</RefSource><PMID Version="1">27959613</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2008 Apr 16;100(8):542-51</RefSource><PMID Version="1">18398097</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2012 May;19(5):1508-16</RefSource><PMID Version="1">22193884</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2013 Jan 10;31(2):195-202</RefSource><PMID Version="1">23233719</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2011 Sep;12(9):852-61</RefSource><PMID Version="1">21862407</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2012 Feb 18;379(9816):633-40</RefSource><PMID Version="1">22257673</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2016 Jul;158(2):361-71</RefSource><PMID Version="1">27357813</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res. 2014 Jun 03;16(3):211</RefSource><PMID Version="1">25093514</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Jan 26;366(4):299-309</RefSource><PMID Version="1">22276820</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2009 Jan;113(1):145-51</RefSource><PMID Version="1">18264759</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Jan 26;366(4):310-20</RefSource><PMID Version="1">22276821</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 Jul 16;373(3):209-19</RefSource><PMID Version="1">26030518</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Clin Oncol. 2012 Sep;9(9):529-41</RefSource><PMID Version="1">22825374</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2016 Jul 20;34(21):2460-7</RefSource><PMID Version="1">27138582</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst Monogr. 2015 May;2015 (51):51-5</RefSource><PMID Version="1">26063887</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2008 Apr 17;358(16):1663-71</RefSource><PMID Version="1">18420499</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2011 Mar 1;17(5):1082-9</RefSource><PMID Version="1">21233401</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 May 20;30(15):1796-804</RefSource><PMID Version="1">22508812</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2012 Oct 4;490(7418):61-70</RefSource><PMID Version="1">23000897</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2001 Mar 15;344(11):783-92</RefSource><PMID Version="1">11248153</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am Soc Clin Oncol Educ Book. 2016;35:e40-54</RefSource><PMID Version="1">27249746</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 Jan 29;372(5):436-46</RefSource><PMID Version="1">25495490</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2003 Apr 15;21(8):1431-9</RefSource><PMID Version="1">12668651</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Compr Canc Netw. 2017 Apr;15(4):433-451</RefSource><PMID Version="1">28404755</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2012 Mar 13;106(6):1234-8</RefSource><PMID Version="1">22333603</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2017 Jan 10;35(2):141-148</RefSource><PMID Version="1">28056202</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Cancer. 2008 Feb 26;8:62</RefSource><PMID Version="1">18302747</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2014 May;25(5):998-1004</RefSource><PMID Version="1">24585721</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2014 Nov 1;20(21):5359-64</RefSource><PMID Version="1">25204553</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2012 Apr;13(4):345-52</RefSource><PMID Version="1">22265697</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2015 Sep;26 Suppl 5:v8-30</RefSource><PMID Version="1">26314782</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA Oncol. 2015 Oct;1(7):875-6</RefSource><PMID Version="1">26181139</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2007 May 1;109(9):1721-8</RefSource><PMID Version="1">17387718</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Expert Opin Investig Drugs. 2008 Oct;17(10):1553-8</RefSource><PMID Version="1">18808314</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2015 Jan;16(1):25-35</RefSource><PMID Version="1">25524798</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochim Biophys Acta. 2014 Aug;1846(1):201-15</RefSource><PMID Version="1">25026313</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Lett. 2007 Oct 18;256(1):1-24</RefSource><PMID Version="1">17475399</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 1989 Jun;7(6):710-7</RefSource><PMID Version="1">2715802</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2013 Oct 10;31(29):3623-30</RefSource><PMID Version="1">24002511</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12117-22</RefSource><PMID Version="1">17626183</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2013 Mar 1;31(7):860-7</RefSource><PMID Version="1">23341518</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mod Pathol. 2010 Feb;23(2):205-12</RefSource><PMID Version="1">19898421</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2015 Jul;26(7):1333-40</RefSource><PMID Version="1">25935793</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2014 Jun;145(3):707-14</RefSource><PMID Version="1">24807107</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacol Ther. 2014 Jul;143(1):1-11</RefSource><PMID Version="1">24513440</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Feb 10;26(5):778-85</RefSource><PMID Version="1">18258986</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2016 Nov;17 (11):1579-1589</RefSource><PMID Version="1">27617661</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2002 Jun 15;20(12):2812-23</RefSource><PMID Version="1">12065558</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2016 Jul 7;375(1):23-34</RefSource><PMID Version="1">27406347</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2016 Mar;17(3):367-77</RefSource><PMID Version="1">26874901</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2014 Feb 14;9(2):e88557</RefSource><PMID Version="1">24551119</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Annu Rev Med. 2011;62:233-47</RefSource><PMID Version="1">20887199</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2013 Apr 30;108(8):1587-92</RefSource><PMID Version="1">23579222</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2005 Apr 14;434(7035):917-21</RefSource><PMID Version="1">15829967</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2005 May 14-20;365(9472):1687-717</RefSource><PMID Version="1">15894097</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2011 Jul;128(2):347-56</RefSource><PMID Version="1">20730488</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2013 Nov 1;31(31):3997-4013</RefSource><PMID Version="1">24101045</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2011 Oct 10;29(29):3877-84</RefSource><PMID Version="1">21911726</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncotarget. 2016 Jun 21;7(25):37680-37692</RefSource><PMID Version="1">27129177</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2016 Aug 1;22(15):3764-73</RefSource><PMID Version="1">26957554</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2013 Mar 20;31(9):1157-63</RefSource><PMID Version="1">23382472</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2014 Dec;25(12):2363-72</RefSource><PMID Version="1">25223482</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Intern Emerg Med. 2016 Feb;11(1):123-40</RefSource><PMID Version="1">26712595</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2014 Dec 10;32(35):3948-58</RefSource><PMID Version="1">25349302</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Immunol Res. 2014 Apr;2(4):361-70</RefSource><PMID Version="1">24764583</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34</RefSource><PMID Version="1">17671126</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2013 Sep;14(10):933-42</RefSource><PMID Version="1">23932548</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 Aug 1;30(22):2718-24</RefSource><PMID Version="1">22565002</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2016 Apr 1;34(10 ):1034-42</RefSource><PMID Version="1">26598744</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2014 Sep;15(10):1137-46</RefSource><PMID Version="1">25130998</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Breast Cancer. 2014 Jun;14(3):154-60</RefSource><PMID Version="1">24512858</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74</RefSource><PMID Version="1">11553815</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Breast Cancer. 2011 Oct;11(5):275-82</RefSource><PMID Version="1">21729661</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2013 Nov;14(12):1183-92</RefSource><PMID Version="1">24095300</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Mol Med. 2002 Dec;8(12):571-6</RefSource><PMID Version="1">12470990</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocr Relat Cancer. 2011 Jul 04;18(4):C19-24</RefSource><PMID Version="1">21613412</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 1998 Feb;16(2):462-9</RefSource><PMID Version="1">9469329</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2015 Jan 1;33(1):13-21</RefSource><PMID Version="1">25092775</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2012 Mar;122(3):1066-75</RefSource><PMID Version="1">22326955</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2006 Feb 23;354(8):809-20</RefSource><PMID Version="1">16495393</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Dec 1;27(34):5838-47</RefSource><PMID Version="1">19884552</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2006 Jun 7;295(21):2492-502</RefSource><PMID Version="1">16757721</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Cancer. 2015 May;15(5):261-75</RefSource><PMID Version="1">25907219</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mod Pathol. 2011 Jul;24(7):924-31</RefSource><PMID Version="1">21552212</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2011 Apr;22(4):870-6</RefSource><PMID Version="1">20937646</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 Nov 19;373(21):2005-14</RefSource><PMID Version="1">26412349</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28616845</ArticleId><ArticleId IdType="doi">10.1007/s40265-017-0774-5</ArticleId><ArticleId IdType="pii">10.1007/s40265-017-0774-5</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Pays-Bas</li></country><region><li>Hollande-Septentrionale</li></region><settlement><li>Amsterdam</li></settlement></list><tree><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Steenbruggen, Tessa G" sort="Steenbruggen, Tessa G" uniqKey="Steenbruggen T" first="Tessa G" last="Steenbruggen">Tessa G. Steenbruggen</name></region><name sortKey="Kok, Marleen" sort="Kok, Marleen" uniqKey="Kok M" first="Marleen" last="Kok">Marleen Kok</name><name sortKey="Linn, Sabine C" sort="Linn, Sabine C" uniqKey="Linn S" first="Sabine C" last="Linn">Sabine C. Linn</name><name sortKey="Smorenburg, Carolien H" sort="Smorenburg, Carolien H" uniqKey="Smorenburg C" first="Carolien H" last="Smorenburg">Carolien H. Smorenburg</name><name sortKey="Sonke, Gabe S" sort="Sonke, Gabe S" uniqKey="Sonke G" first="Gabe S" last="Sonke">Gabe S. Sonke</name><name sortKey="Van Ramshorst, Mette S" sort="Van Ramshorst, Mette S" uniqKey="Van Ramshorst M" first="Mette S" last="Van Ramshorst">Mette S. Van Ramshorst</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 009196 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 009196 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:28616845
|texte= Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:28616845" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |